Gene Therapy Reverses Aging in Human Eyes, Restoring Vision in Early Trial
Life Biosciences has administered a gene therapy called ER-100 to three patients with glaucoma, resulting in improved vision for two participants after eight weeks. The treatment, based on research by Harvard geneticist David Sinclair, uses epigenetic reprogramming to rejuvenate aging retinal ganglion cells. While the Phase 1 trial focuses on safety, preliminary results suggest the therapy could reverse age-related vision loss, with potential applications for other organs like the liver.
Key points
- Life Biosciences is testing ER-100, a gene therapy designed to reverse aging in retinal ganglion cells, which are damaged in glaucoma.
- In a Phase 1 trial involving three participants, two reported meaningful improvements in their visual fields eight weeks after treatment.
- The therapy is based on 2020 research by David Sinclair and Yuancheng Lu, which showed that expressing three transcription factor genes could restore youthful attributes to mouse ganglion cells.
- Sharon Rosenzweig-Lipson, chief scientific officer at Life Biosciences, stated that the visual improvements are encouraging as the company advances the ER-100 program.
- Sinclair noted that the epigenetic machinery targeted by the therapy exists in cells throughout the body, suggesting potential applications for age-related diseases in organs like the liver.
Background
This development follows earlier research into regenerative medicine for eye diseases, such as stem cell transplants for macular degeneration at the University of Michigan, which also showed unexpected vision improvements during safety trials. The broader field of epigenetic reprogramming has gained attention for its potential to reverse aging in various tissues, moving beyond initial mouse models to human clinical trials.
Why it matters
The success of ER-100 in restoring vision could mark a significant shift in treating age-related eye diseases, moving from managing symptoms to reversing cellular aging. If the epigenetic approach proves effective in other organs, it could lead to a new class of medicines for age-related diseases across the body, potentially addressing conditions like liver disease and other degenerative disorders.
What to watch
Life Biosciences will continue to advance the ER-100 program, likely moving to larger trials to confirm efficacy and safety. Researchers will also explore the application of epigenetic reprogramming in other organs, such as the liver, to determine if the therapy can be developed into a platform for treating multiple age-related diseases.
Want the full story? Read the original reporting
Read on Yahoo